TRR 338 LETSimmun
Second funding period approved
21.11.2025
Established in 2021, the Collaborative Research Center Transregio LETSIMMUN has been successfully approved for its second funding period. Dirk Busch from TUM will remain the spokesperson, and Marion Subklewe will serve as the new co-spokesperson at LMU Munich in the upcoming funding phase.
ABOUT LETSimmun
The strategic approach of LETSimmun is to explore and combine lymphocyte engineering technologies and targets by pursuing a holistic approach. Researchers and clinician-scientist with already proven and internationally recognized experiences in clinical lymphocyte engineering come together with young talents and interdisciplinary experts with crucial expertise in defined areas that represent promising engineering interfaces and technologies.
https://letsimmun.de/